BIO.News Newsletter

Today, we have details on the National Security Commission on Emerging Biotechnology’s new report—and why tariffs still threaten biotech, including pharma and ag. (816 words, 4 minutes, 4 seconds)

A busy week brings discussions on tariffs, PBMs, and many hearings ahead. (896 words, 4 minutes, 28 seconds)

Another busy week begins with BIO’s new survey of member views on tariffs and a BIO Board member’s congressional testimony on how legislation can help small biotechs. (747 words, 3 minutes, 44 seconds)

A new report released by BIO highlights the potential of the bioeconomy – if we give it support. Plus, more news on federal funding for bird flu interventions, the need to invest in women's health, and more. (691 words, 3 minutes, 27 seconds)

Patient advocates explain why the Pediatric Priority Review Voucher (PPRV) Program must be reauthorized, and National Ag Day highlights the links between biotech and agriculture. (982 words, 4 minutes, 52 seconds)P.S. If you’re in D.C., BIO is sponsoring today’s AgriPulse 2025 Ag & Food Policy Summit, "Navigating Taxes, Trade and Technology: What's Ahead for Food & Agriculture." BIO members BASF and Pivot Bio will also speak.

BIO President & CEO John F. Crowley writes Congress to urge PPRV passage; plus a deep dive into the impact of autoimmune disease on women. (761 words, 3 minutes, 48 seconds)

A busy week in Washington, D.C., brought legislation to fix the Inflation Reduction Act “pill penalty,” bipartisan calls for PBM reform, and BIO CEO John F. Crowley explaining why Congress needs to act to support rare disease drug development. (1012 words, 5 minutes, 3 seconds)

We’re getting ready for Rare Disease Day (February 28) with a look at how policy can support patients and how BIO is engaging with the FDA. (960 words, 4 minutes, 48 seconds)

ICYMI: PBM legislation was reintroduced in the Senate. We have details, plus more on the biotech market outlook, the importance of Accelerated Approval, and what a new shrimp vaccine tells us about innate immunity. (718 words, 3 minutes, 35 seconds)

We recap Day 2 of the 2025 BIO CEO and Investor Conference in New York with a look at what we can expect from the new administration and Congress, as well as promising schizophrenia developments. (347 words, 1 minute, 44 seconds)